Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
ahead, apatinib, cancellation, capacity, Carlo, cellular, cytotoxicity, eleven, exercisable, exercise, Fudan, Hengrui, Incyte, larger, maximum, Medicine, Monte, monthly, nonqualified, occupancy, Ono, Pacific, pause, pharmacokinetic, ratio, simulation, sintilimab, surface, survival, tender, tendered, trough, Tyvyt, unamortized, underlying
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view